BIO-Europe Spring EBD Group BIO Image Map
Share:
Email this page Share this on LinkedIn Share this on Twitter

BIO-Europe Spring® 2015 Press Releases

December 16, 2014Paris, France will host BIO-Europe Spring® 2015 international life science partnering conference The ninth annual BIO-Europe Spring® conference will be held March 9–11, 2015 in Paris, France at the Paris expo Porte de Versailles conference center. This is the first time Paris will host a life science industry event of this scale, and it is expected to draw a large number of established biotech and early stage companies desiring to form business partnerships with invest...  more ►

November 20, 2014Spotlight on Paris Business Facts The Paris region is Europe's No. 1 business region with 842,000 businesses, from high tech sectors to traditional industrial activities. Paris is an innovation hotspot and has eight competitive clusters enhancing innovation, and the most generous research tax credits in Europe. There were 4,800 patents filed in the Paris region in 2012. 500 international companies enjoy the...  more ►


partnering360® Blog

January 26, 2015 Spotlight on the MedTech Industry The Medtech Trends and MoneyTree™ Investment Data report has recently been published and the medtech industry is profiting from more deals – however, the number of medtech companies receiving actual investment is down – so the fewer companies that are seeing investment are seeing more... more ►

January 23, 2015 Recursion Pharmaceuticals: Innovative alternative to drug discovery Investment in biotech companies is increasing.  A recent article at Drug Discovery and Development shares that biotech investing was up 26% at the beginning of 2014 which equaled $2.93 billion.  Many believe it is because investments are shifting from digital to problems that need to be solved on... more ►

January 14, 2015 Biotech Showcase™ 2015 Day Three Biotech Showcase™ 2015 day three started off with the panel “Apps as drugs” moderated by Steve Dickman of CBT Advisors which gave insight into online and mobile apps and programs that augment disease platforms. There was interest in whether the apps would replace or work in conjunction with... more ►

January 14, 2015 Biotech Showcase™ 2015: Days 1 and 2 Highlights Biotech Showcase™ 2015 is in full swing on this second conference day. An estimated 2,100 delegates have been participating in 4,400 one-to-one partnering meetings this year, an all-time high. The Alliance for Regenerative Medicine’s (ARM)“Regenerative Medicine and Advanced Therapies State of... more ►

January 12, 2015 ARM State of the Industry Briefing gives clear evidence that regen med/advanced therapies are the next big thing in biotech Biotech Showcase™ 2015 kicked off today with the Alliance for Regenerative Medicine’s (ARM) Regenerative Medicine and Advanced Therapies State of the Industry Briefing. Edward Lanphier, President and CEO of Sangamo BioScience and the new Chair of the Alliance for Regenerative Medicine gave... more ►



partnering360:Insight Latest headlines from partnering360:Insight

January 22, 2015 Life sciences democratize research and investing Non-accredited investors are beginning to have the opportunity to invest in biotech, thanks to some innovative new financing mechanisms and the growing democratization of healthcare, according to panelists at the Biotech Showcase™ 2015 financing session. more ►

January 16, 2015 Are old financing models enough? Last year saw more than USD 400 billion returned to investors through IPO exits and a bevy of new venture funds created, but this doesn’t signal a return to business as usual. Instead biotech financing in the future must continue to look to innovative strategies and must address reimbursement questions ever earlier in the race to attract funds, according to panelists at a Biotech Showcase™ 2015 lunch plenary. more ►

January 16, 2015 Regenerative medicine creating tangible value Regenerative medicine is beginning to add real value to healthcare not just by treating disease, but by curing disease. Most people—even those in the industry—don’t realize that more than 60 regenerative products have been approved, said Edward Lanphier. Some 500 companies are operating in this space globally, with 375 ongoing clinical trials. Of those, 340 are in Phase I or Phase II. Therefore, a great many products can be expected to be commercialized in the next few years. more ►

January 16, 2015 Perceptions of value and success There’s no single definition of value in the life sciences. Big pharma, investment bankers and venture capitalists each have different goals that affect their perception of value and guide their investment decisions. Panelists at a luncheon plenary session at Biotech Showcase™ 2015 made that point patently evident. more ►

January 16, 2015 The new immuno-oncology revolution Immuno-oncology is new again, fueled by research that has many scientists thinking a cure for cancer may be possible within their lifetimes. After the cancer vaccine misses of seven years ago, investors’ interests are once again piqued. The challenge is identifying exactly where in this fast-moving, complicated space to invest, according to Stephen Dunn, President and Senior Managing Partner, LifeTech Capital, speaking at Biotech Showcase™ 2015. more ►



Arrow Up


 
 
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2015 EBD GmbH
Privacy Policy
Terms of Use
BIO-Europe Spring EBD Group BIO Image Map